Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Alcyone Study

Autor:	Maria-Victoria Mateos, Jesús San-Miguel, Michele Cavo, Joan Bladé Creixenti, Kenshi Suzuki, Andrzej Jakubowiak, Stefan Knop, Chantal Doyen, Paulo Lucio, Zsolt Nagy, Ludek Pour, Sebastian Grosicki, Andre H Crepaldi, Anna Marina Liberati, Philip Campbell, Tatiana Shelekhova, Sung-Soo Yoon, Genadi Iosava, Tomoaki Fujisaki, Mamta Garg, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Meletios A. Dimopoulos
Rok vydání:	2022
Předmět:	Immunology Cell Biology Hematology Biochemistry
Zdroj:	Blood. 140:10157-10159
ISSN:	1528-0020 0006-4971
DOI:	10.1182/blood-2022-163347
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::194c84ba1f0eca689afad6d9a795370c https://doi.org/10.1182/blood-2022-163347 Zobrazit plný text záznamu